Health Care [ 12/12 ] | Biotechnology [ 64/74 ]
NASDAQ | Common Stock
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria.
It has a research collaboration and license agreement with F.
Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 24 | -0.32 Increased by 0.00% | -0.41 Increased by +21.95% |
| May 14, 24 | -0.25 Increased by +44.44% | -0.42 Increased by +40.48% |
| Mar 7, 24 | -0.27 Increased by +30.77% | -0.39 Increased by +30.77% |
| Nov 9, 23 | -0.35 Decreased by -138.04% | -0.29 Decreased by -20.69% |
| Aug 8, 23 | -0.32 Increased by +53.62% | -0.53 Increased by +39.62% |
| May 9, 23 | -0.45 Increased by +51.61% | -0.45 |
| Mar 9, 23 | -0.39 Decreased by -2.05 K% | -0.22 Decreased by -77.27% |
| Nov 10, 22 | 0.92 Increased by +235.29% | -0.65 Increased by +241.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 71.75 M Increased by +667.19% | 20.23 M Increased by +163.68% | Increased by +28.20% Increased by +108.30% |
| Jun 30, 24 | 25.97 M Increased by +29.78% | -31.37 M Decreased by -14.26% | Decreased by -120.78% Increased by +11.96% |
| Mar 31, 24 | 28.14 M Increased by +172.09% | -24.27 M Increased by +39.63% | Decreased by -86.26% Increased by +77.81% |
| Dec 31, 23 | 25.00 M Increased by +151.95% | -23.99 M Increased by +28.00% | Decreased by -95.98% Increased by +71.42% |
| Sep 30, 23 | 9.35 M Decreased by -91.96% | -31.78 M Decreased by -145.13% | Decreased by -339.80% Decreased by -661.30% |
| Jun 30, 23 | 20.01 M Increased by +641.22% | -27.46 M Increased by +38.34% | Decreased by -137.19% Increased by +91.68% |
| Mar 31, 23 | 10.34 M Increased by +620.77% | -40.21 M Increased by +32.03% | Decreased by -388.73% Increased by +90.57% |
| Dec 31, 22 | 9.92 M Increased by +31.66 K% | -33.32 M Decreased by -2.27 M% | Decreased by -335.85% Decreased by -7.24 K% |